287 related articles for article (PubMed ID: 32633024)
41. Anti-neuroinflammatory efficacy of the aldose reductase inhibitor FMHM via phospholipase C/protein kinase C-dependent NF-κB and MAPK pathways.
Zeng KW; Li J; Dong X; Wang YH; Ma ZZ; Jiang Y; Jin HW; Tu PF
Toxicol Appl Pharmacol; 2013 Nov; 273(1):159-71. PubMed ID: 24021941
[TBL] [Abstract][Full Text] [Related]
42. Design, synthesis, structure-activity relationships and X-ray structural studies of novel 1-oxopyrimido[4,5-c]quinoline-2-acetic acid derivatives as selective and potent inhibitors of human aldose reductase.
Crespo I; Giménez-Dejoz J; Porté S; Cousido-Siah A; Mitschler A; Podjarny A; Pratsinis H; Kletsas D; Parés X; Ruiz FX; Metwally K; Farrés J
Eur J Med Chem; 2018 May; 152():160-174. PubMed ID: 29705708
[TBL] [Abstract][Full Text] [Related]
43. Selectivity determinants of inhibitor binding to the tumour marker human aldose reductase-like protein (AKR1B10) discovered from molecular docking and database screening.
Zhao HT; Soda M; Endo S; Hara A; El-Kabbani O
Eur J Med Chem; 2010 Sep; 45(9):4354-7. PubMed ID: 20538382
[TBL] [Abstract][Full Text] [Related]
44. Exploring the interactional details between aldose reductase (AKR1B1) and 3-Mercapto-5H-1,2,4-triazino[5,6-b]indole-5-acetic acid through molecular dynamics simulations.
Zhan JY; Ma K; Zheng QC; Yang GH; Zhang HX
J Biomol Struct Dyn; 2019 Apr; 37(7):1724-1735. PubMed ID: 29671687
[TBL] [Abstract][Full Text] [Related]
45. Discovery of Phenylcarbamoylazinane-1,2,4-Triazole Amides Derivatives as the Potential Inhibitors of Aldo-Keto Reductases (AKR1B1 & AKRB10): Potential Lead Molecules for Treatment of Colon Cancer.
Saeed A; Ejaz SA; Sarfraz M; Tamam N; Siddique F; Riaz N; Qais FA; Chtita S; Iqbal J
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807227
[TBL] [Abstract][Full Text] [Related]
46. Decreased expression of cyclic adenosine monophosphate-regulated aldose reductase (AKR1B1) is associated with malignancy in human sporadic adrenocortical tumors.
Lefrançois-Martinez AM; Bertherat J; Val P; Tournaire C; Gallo-Payet N; Hyndman D; Veyssière G; Bertagna X; Jean C; Martinez A
J Clin Endocrinol Metab; 2004 Jun; 89(6):3010-9. PubMed ID: 15181092
[TBL] [Abstract][Full Text] [Related]
47. Kinetic studies of AKR1B10, human aldose reductase-like protein: endogenous substrates and inhibition by steroids.
Endo S; Matsunaga T; Mamiya H; Ohta C; Soda M; Kitade Y; Tajima K; Zhao HT; El-Kabbani O; Hara A
Arch Biochem Biophys; 2009 Jul; 487(1):1-9. PubMed ID: 19464995
[TBL] [Abstract][Full Text] [Related]
48. Aldose reductase C-106T polymorphism is associated with the risk of essential hypertension.
Wang Y; Yu M; Mo L; Li Z; Wang J; Zhou HH; Ouyang DS
Gene; 2016 Oct; 591(1):65-68. PubMed ID: 27343777
[TBL] [Abstract][Full Text] [Related]
49. Decreased levels of AKR1B1 and AKR1B10 in cancerous endometrium compared to adjacent non-cancerous tissue.
Hevir N; Sinkovec J; Lanišnik Rižner T
Chem Biol Interact; 2013 Feb; 202(1-3):226-33. PubMed ID: 23146748
[TBL] [Abstract][Full Text] [Related]
50. Aldose Reductase Differential Inhibitors in Green Tea.
Balestri F; Poli G; Pineschi C; Moschini R; Cappiello M; Mura U; Tuccinardi T; Del Corso A
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32640594
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of the prostaglandin F synthase activity of human and bovine aldo-keto reductases: AKR1A1s complement AKR1B1s as potent PGF synthases.
Lacroix Pépin N; Chapdelaine P; Fortier MA
Prostaglandins Other Lipid Mediat; 2013 Oct; 106():124-32. PubMed ID: 23747692
[TBL] [Abstract][Full Text] [Related]
52. EPS15-AS1 Inhibits AKR1B1 Expression to Enhance Ferroptosis in Hepatocellular Carcinoma Cells.
Man Q; Zhang G; Chen X; Na SR; Bai S; Zhi H; Sun L; Pang H
J Cancer; 2024; 15(4):1030-1040. PubMed ID: 38230218
[TBL] [Abstract][Full Text] [Related]
53. Asthma and allergic rhinitis associate with the rs2229542 variant that induces a p.Lys90Glu mutation and compromises AKR1B1 protein levels.
García-Martín E; Sánchez-Gómez FJ; Amo G; García Menaya J; Cordobés C; Ayuso P; Plaza Serón MC; Blanca M; Campo P; Esguevillas G; Pajares MA; G Agúndez JA; Pérez-Sala D
Hum Mutat; 2018 Aug; 39(8):1081-1091. PubMed ID: 29726087
[TBL] [Abstract][Full Text] [Related]
54. Expression of the Aldo-Ketoreductases AKR1B1 and AKR1B10 in Human Cancers.
Laffin B; Petrash JM
Front Pharmacol; 2012; 3():104. PubMed ID: 22685431
[TBL] [Abstract][Full Text] [Related]
55. Design and synthesis of polyhydroxy steroids as selective inhibitors against AKR1B10 and molecular docking.
Chen W; Chen X; Zhou S; Zhang H; Wang L; Xu J; Hu X; Yin W; Yan G; Zhang J
Steroids; 2016 Jun; 110():1-8. PubMed ID: 26968129
[TBL] [Abstract][Full Text] [Related]
56. Substrate specificity and catalytic efficiency of aldo-keto reductases with phospholipid aldehydes.
Spite M; Baba SP; Ahmed Y; Barski OA; Nijhawan K; Petrash JM; Bhatnagar A; Srivastava S
Biochem J; 2007 Jul; 405(1):95-105. PubMed ID: 17381426
[TBL] [Abstract][Full Text] [Related]
57. Gedunin, A Neem Limonoid in Combination with Epalrestat Inhibits Cancer Hallmarks by Attenuating Aldose Reductase-Driven Oncogenic Signaling in SCC131 Oral Cancer Cells.
Tanagala KKK; Baba AB; Kowshik J; Reddy GB; Nagini S
Anticancer Agents Med Chem; 2018; 18(14):2042-2052. PubMed ID: 30062975
[TBL] [Abstract][Full Text] [Related]
58. Comprehensive analysis of prostaglandin metabolic enzyme expression during pregnancy and the characterization of AKR1B1 as a prostaglandin F synthase at the maternal-conceptus interface in pigs.
Seo H; Choi Y; Shim J; Yoo I; Ka H
Biol Reprod; 2014 May; 90(5):99. PubMed ID: 24695626
[TBL] [Abstract][Full Text] [Related]
59. Aldo-keto reductases as modulators of stress response.
Chang Q; Harter TM; Rikimaru LT; Petrash JM
Chem Biol Interact; 2003 Feb; 143-144():325-32. PubMed ID: 12604219
[TBL] [Abstract][Full Text] [Related]
60. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
